G1 Therapeutics is enrolling two Phase 1b/2a clinical trials in SCLC

Study 02 - For patients not previously treated with chemotherapy.

Study 02 is for patients diagnosed with SCLC who have not yet received chemotherapy. For these patients, the investigational medicine will be administered just prior to the carboplatin and etoposide chemotherapy. In this study, patients will have 50/50 chance (like the flip of a coin) to receive the investigational medicine or placebo with the standard chemotherapy. The study is currently enrolling in the phase 2a randomized portion of the study, and approximately 70 patients will be enrolled.

Study 03 - For patients previously treated with chemotherapy.

Study 03 is for patients diagnosed with SCLC who have already received chemotherapy. For these patients, the investigational medicine or placebo will be administered just prior to topotecan chemotherapy. The study is enrolling in the phase 2a randomized portion of the study, and approximately 60 patients will be enrolled.

If you have been diagnosed with SCLC, sign up to be contacted for screening into these studies. 

You can also call 855-216-0159 to speak to a Clinical Trial Navigator. They are available Monday – Friday, 9am to 6pm ET.